
Edwards Lifesciences Corp statistics
$107.15+1.28%Close 13 Nov 2026 · Market value $61.47B
Valuation and share-price figures are struck on the latest close (13 Nov 2026); the others are read from the company's reports. A figure that cannot be worked out, such as a P/E after a loss, is left out.
Valuation
Edwards Lifesciences Corp is valued at $61.47B on its latest close. Its price is 60.2 times its earnings.
| Market value | $61.47B |
|---|
| Enterprise value | $57.84B |
|---|
| Price / earnings | 60.19 |
|---|
| Price / sales | 9.21 |
|---|
| Price / book | 5.66 |
|---|
| EV / EBITDA | 35.87 |
|---|
| EV / sales | 8.66 |
|---|
| Price / free cash flow | 43.16 |
|---|
| Price / free cash flow, own 5-year average | 68.37 |
|---|
| EV / EBIT | 39.92 |
|---|
| EV / free cash flow | 40.40 |
|---|
| Free cash flow yield | 2.3% |
|---|
Share price
| Latest close | $107.15 |
|---|
| Day's change | +1.3% |
|---|
| 52-week high | $107.69 |
|---|
| 52-week low | $74.66 |
|---|
| From 52-week high | −0.5% |
|---|
| Return · 1 month | +23.7% |
|---|
| Return · 3 months | +19.3% |
|---|
| Return · year to date | +25.7% |
|---|
| Return · 1 year | +25.2% |
|---|
| Beta · 1 year against the S&P 500 | 0.54 |
|---|
| 50-day average | $90.42 |
|---|
| 200-day average | $86.33 |
|---|
| RSI 14 | 80.3 |
|---|
| Average volume · 20 sessions | 4.8M |
|---|
Margins and returns
For fiscal 2025, as filed.
| Gross margin | 78.0% |
|---|
| Operating margin | 20.8% |
|---|
| Net margin | 17.7% |
|---|
| Free cash flow margin | 22.0% |
|---|
| Return on equity | 10.6% |
|---|
| Return on assets | 7.8% |
|---|
| Return on invested capital | 13.7% |
|---|
| Return on invested capital, 5-year average | 19.7% |
|---|
| Return on capital employed | 10.8% |
|---|
| Stock-based compensation / revenue | 2.6% |
|---|
Financial position
At the end of fiscal 2025.
| Cash and equivalents | $2.94B |
|---|
| Total debt | $705.4M |
|---|
| Net debt | −$3.52B |
|---|
| Current ratio | 3.72 |
|---|
| Quick ratio | 3.44 |
|---|
| Debt / equity | 0.07 |
|---|
| Net debt / EBITDA | −2.48 |
|---|
| Interest coverage | 61.97 |
|---|
Growth
| Revenue, latest quarter on a year | +10.5% |
|---|
| Revenue, twelve months on a year | +13.4% |
|---|
| EPS, latest quarter on a year | +6.0% |
|---|
| EPS, twelve months on a year | −24.2% |
|---|
| Revenue, 5-year compound | +6.7% |
|---|
| Revenue, 10-year compound | +9.3% |
|---|
| Net income, 5-year compound | +5.4% |
|---|
| Free cash flow, 5-year compound | +15.6% |
|---|
| EPS, 5-year compound | +7.1% |
|---|
Shares and dividends
For fiscal 2025, as filed.
| Diluted shares | 586M |
|---|
| Shares outstanding, 5-year compound | −1.5% |
|---|
| Net share repurchases | $804.2M |
|---|
Taxes
For fiscal 2025, as filed.
| Income tax expense | $216.9M |
|---|
| Effective tax rate | 17.0% |
|---|
EW in the terminal
Valuation against the company's own history, a cash-flow valuation, peers, charts and alerts.